SHAREHOLDER ALERT: WeissLaw LLP Investigates Adamas Pharmaceuticals, Inc.

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS) in connection with the proposed acquisition of the Company by Supernus Pharmaceuticals, Inc. ("Supernus") (NASDAQ: SUPN), via a tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $8.10 per share in cash payable at closing, plus two non-tradable contingent value rights collectively worth up to $1.00 per share in cash, payable upon achieving certain net sales thresholds of the Company's lead product, GOCOVRI, for each share of Adamas common stock that they hold. 

If you own Adamas shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

Read more at prnewswire.com